218 related articles for article (PubMed ID: 23287861)
1. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.
Ghobrial IM; Campigotto F; Murphy TJ; Boswell EN; Banwait R; Azab F; Chuma S; Kunsman J; Donovan A; Masood F; Warren D; Rodig S; Anderson KC; Richardson PG; Weller E; Matous J
Blood; 2013 Feb; 121(8):1296-303. PubMed ID: 23287861
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
3. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
Thomas S; Aggarwal R; Jahan T; Ryan C; Troung T; Cripps AM; Raha P; Thurn KT; Chen S; Grabowsky JA; Park J; Hwang J; Daud A; Munster PN
Ann Oncol; 2016 May; 27(5):947-52. PubMed ID: 26903311
[TBL] [Abstract][Full Text] [Related]
5. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.
Ghobrial IM; Witzig TE; Gertz M; LaPlant B; Hayman S; Camoriano J; Lacy M; Bergsagel PL; Chuma S; DeAngelo D; Treon SP
Am J Hematol; 2014 Mar; 89(3):237-42. PubMed ID: 24716234
[TBL] [Abstract][Full Text] [Related]
7. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
[TBL] [Abstract][Full Text] [Related]
8. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
Richardson PG; Laubach JP; Lonial S; Moreau P; Yoon SS; Hungria VT; Dimopoulos MA; Beksac M; Alsina M; San-Miguel JF
Expert Rev Anticancer Ther; 2015; 15(7):737-48. PubMed ID: 26051506
[TBL] [Abstract][Full Text] [Related]
9. Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma.
Wahaib K; Beggs AE; Campbell H; Kodali L; Ford PD
Am J Health Syst Pharm; 2016 Apr; 73(7):441-50. PubMed ID: 27001985
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.
Rathkopf DE; Picus J; Hussain A; Ellard S; Chi KN; Nydam T; Allen-Freda E; Mishra KK; Porro MG; Scher HI; Wilding G
Cancer Chemother Pharmacol; 2013 Sep; 72(3):537-44. PubMed ID: 23820963
[TBL] [Abstract][Full Text] [Related]
11. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
[TBL] [Abstract][Full Text] [Related]
12. The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer.
Shapiro GI; Frank R; Dandamudi UB; Hengelage T; Zhao L; Gazi L; Porro MG; Woo MM; Lewis LD
Cancer Chemother Pharmacol; 2012 Feb; 69(2):555-62. PubMed ID: 22057852
[TBL] [Abstract][Full Text] [Related]
13. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
Richardson PG; Schlossman RL; Alsina M; Weber DM; Coutre SE; Gasparetto C; Mukhopadhyay S; Ondovik MS; Khan M; Paley CS; Lonial S
Blood; 2013 Oct; 122(14):2331-7. PubMed ID: 23950178
[TBL] [Abstract][Full Text] [Related]
14. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
Berenson JR; Hilger JD; Yellin O; Boccia RV; Matous J; Dressler K; Ghazal HH; Jamshed S; Kingsley EC; Harb WA; Noga SJ; Nassir Y; Swift RA; Vescio R
Ann Hematol; 2014 Jan; 93(1):89-98. PubMed ID: 24135804
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
Oki Y; Buglio D; Fanale M; Fayad L; Copeland A; Romaguera J; Kwak LW; Pro B; de Castro Faria S; Neelapu S; Fowler N; Hagemeister F; Zhang J; Zhou S; Feng L; Younes A
Clin Cancer Res; 2013 Dec; 19(24):6882-90. PubMed ID: 24097867
[TBL] [Abstract][Full Text] [Related]
16. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
Duvic M; Dummer R; Becker JC; Poulalhon N; Ortiz Romero P; Grazia Bernengo M; Lebbé C; Assaf C; Squier M; Williams D; Marshood M; Tai F; Prince HM
Eur J Cancer; 2013 Jan; 49(2):386-94. PubMed ID: 22981498
[TBL] [Abstract][Full Text] [Related]
17. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
Tan D; Phipps C; Hwang WY; Tan SY; Yeap CH; Chan YH; Tay K; Lim ST; Lee YS; Kumar SG; Ng SC; Fadilah S; Kim WS; Goh YT;
Lancet Haematol; 2015 Aug; 2(8):e326-33. PubMed ID: 26688485
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
Offidani M; Polloni C; Cavallo F; Liberati AM; Ballanti S; Pulini S; Catarini M; Alesiani F; Corvatta L; Gentili S; Caraffa P; Boccadoro M; Leoni P; Palumbo A
Leuk Lymphoma; 2012 Sep; 53(9):1722-7. PubMed ID: 22335534
[TBL] [Abstract][Full Text] [Related]
19. Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.
Barnes JA; Redd R; Fisher DC; Hochberg EP; Takvorian T; Neuberg D; Jacobsen E; Abramson JS
Hematol Oncol; 2018 Oct; 36(4):633-637. PubMed ID: 29956350
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
Ghobrial IM; Hong F; Padmanabhan S; Badros A; Rourke M; Leduc R; Chuma S; Kunsman J; Warren D; Harris B; Sam A; Anderson KC; Richardson PG; Treon SP; Weller E; Matous J
J Clin Oncol; 2010 Mar; 28(8):1422-8. PubMed ID: 20142586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
